Navigation Links
QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
Date:1/9/2012

HILDEN and BERLIN, Germany, January 9, 2012 /PRNewswire/ --

  • Collaboration to create molecular test assessing a person's risk for latent TB progressing to active TB, enabling early treatment and disease outbreak prevention
  • QIAGEN strengthening its leading infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB
  • New assay will use whole blood transcription profiling - a new diagnostic technology developed at the Max Planck Institute's Department of Immunology
  • New molecular test to be run on the QIAsymphony modular automation platform

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed.

Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis, but do not have active tuberculosis. The identification and treatment of these individuals is critical to controlling this disease since approximately 5-10% of latent TB patients are at risk for developing active TB during their lifetime, particularly those with weakened immune systems.  

As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

This new mol
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
2. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
3. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
4. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
5. QIAGEN Acquires Exclusive Licence for Key PI3K gene
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
8. Plexus Awarded Development Contract With QIAGEN
9. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
10. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
11. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 New test innovations will be the ... (IVD) test industry, especially as companies struggle with reimbursement ... more than 25 testing innovations in important disease areas ... IVD products. Kalorama details the new approaches its biennial survey ... In Vitro Diagnostic Tests , 9th Edition . ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... 2014 Currently offering a comprehensive ... D Weighing, Rice Lake, and Ohaus, Pipette.com has ... The Sartorius CPA Semi-Micro Balance is ideal for ... and user-friendly laboratory balance. , Sartorius is a ... laboratory balances are well known for their high ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... 11 Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ... Blair & Company 28th Annual Growth Stock Conference in ... Time., A live webcast of the presentation can ... . The webcast will,be archived for replay following ...
... Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway ... ... Significantly Streamline the Development and Commercialization of Rosetta Genomics, microRNA-based ... Needs to Market and Sell its microRNA-based Tests in the U.S. and ...
... DANBURY, Conn., June 11 Biodel Inc. (Nasdaq:,BIOD) today ... as,a new member of its Board of Directors, effective ... of Diabetes Technology,Consultants where he advises Fortune 500 companies ... welcome Barry to our Board of Directors at such ...
Cached Biology Technology:Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 3Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 4Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 5Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 6Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors 2
(Date:10/25/2014)... 2014 A recent report, "Genetic Testing Market ... and future genetic testing market. A comprehensive introduction of ... in this report. On account of our analysis of ... strengths and challenges; forecast for genetic testing has been ... grow at a CAGR of around 9% during 2013-2018. ...
(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... 20, 2014  Leading identity analyst firm Acuity Market ... the world,s population will have a chip-based National eID ... . Asia , with its ... for more than 60% of all National eID cards ... -- "The Global National eID Industry Report: ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2
... Calif., Nov. 19, 2012 Medbox, Inc. (Ticker: MDBX) ... press release they have received many inquiries from shareholders ... during last week,s volatile trading. These inquiries were responded ... to shareholder rapport. In other news, ...
... media only" box at the end of the release ... mouse model of multiple sclerosis (MS), researchers funded by ... to selectively inhibit the part of the immune system ... fibers and facilitates electrical communication between brain cells. ...
... 16 Penguins that face the bitter cold and icy ... warmth during storms. Mathematicians at the University of California, Merced ... aims solely to minimize its own heat loss. Surprisingly, the ... sharing of heat. The results are published in the online ...
Cached Biology News:Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel 2Research breakthrough selectively represses the immune system 2Research breakthrough selectively represses the immune system 3Research breakthrough selectively represses the immune system 4New model reveals how huddling penguins share heat fairly 2New model reveals how huddling penguins share heat fairly 3
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... application for DNA and protein sequence ... makes complex computational analyses of sequence ... very latest computing technology to set ... are analysed. Features include: Sequence Annotation, ...
... Cytokeratin TYPE II Reacts with most ... epidermal cell keratin of 86 and 58kD ... Broad keratin reactivity is found on human ... Immunogen: Human epidermal cells ...
... The CHEMICON XpressPack™ Colorimetric Detection System ... detection of amplified DNA generated by an ... of a selected target of interest. ... Colorimetric Detection System is a hybridization capture ...
Biology Products: